Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kura Oncology, Inc.KURA · Entity 4871 | SVP, Finance & Accounting | January 27, 2026 | January 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kura Oncology, Inc.
Report date January 27, 2026 · Filed January 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,167 |
Ending reported balance
After 2026-01-27 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-01-27 · Sale · Disposed 2,226 · Balance 150,083 F1: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Row 2 · 2026-01-27 · Sale · Disposed 1,114 · Balance 148,969 F2: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Row 3 · 2026-01-27 · Sale · Disposed 695 · Balance 148,274 F3: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Row 4 · 2026-01-27 · Sale · Disposed 2,226 · Balance 146,048 F4: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. Row 5 · 2026-01-27 · Sale · Disposed 881 · Balance 145,167 F5: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22. |
| Common StockSEC Table I · non-derivative | Indirectspouse's 401(k) | 500 |
Reported balance
Holding disclosure · report date 2026-01-27 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 500 |
Filing footnotes · ownership attribution and instrument terms
F1: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24.
F2: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23.
F3: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.
F4: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25.
F5: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 881 | $8.46 | $7,453.88 |
DisclosureSEC source: 0001193125-26-025302 · ownership.xml · nonDerivative · entry 5 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,167 F5 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,226 | $8.46 | $18,833.52 |
DisclosureSEC source: 0001193125-26-025302 · ownership.xml · nonDerivative · entry 4 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,048 F4 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 695 | $8.46 | $5,880.19 |
DisclosureSEC source: 0001193125-26-025302 · ownership.xml · nonDerivative · entry 3 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,274 F3 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,114 | $8.46 | $9,425.22 |
DisclosureSEC source: 0001193125-26-025302 · ownership.xml · nonDerivative · entry 2 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,969 F2 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 02:35 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,226 | $8.46 | $18,833.52 |
DisclosureSEC source: 0001193125-26-025302 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,083 F1 · acquired: Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 42,500 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004569 · ownership.xml · derivative · entry 3 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2036-01-01 F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-004569 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,309 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/27, 1/26/28, 1/26/29 and 1/26/30. F2 · balance_after: Includes 802 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,539 | $11.18 | $50,731.95 |
DisclosureSEC source: 0001193125-25-283562 · ownership.xml · nonDerivative · entry 2 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,257 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 24,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-283562 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,796 Read SEC document |
| September 29, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 4,541 | $8.94 | $40,606.53 |
DisclosureSEC source: 0001193125-25-223662 · ownership.xml · nonDerivative · entry 2 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,829 F2 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on September 27, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| September 27, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 24,966 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-223662 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,370 F1 · balance_after: Includes 1,211 shares acquired on May 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:54 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,122 | $7.87 | $8,832.27 |
DisclosureSEC source: 0000950170-25-010137 · ownership.xml · nonDerivative · entry 4 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,193 F4 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:54 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 699 | $7.87 | $5,502.46 |
DisclosureSEC source: 0000950170-25-010137 · ownership.xml · nonDerivative · entry 3 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,315 F3 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:54 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 887 | $7.87 | $6,982.38 |
DisclosureSEC source: 0000950170-25-010137 · ownership.xml · nonDerivative · entry 2 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,014 F2 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 01:54 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 2,241 | $7.87 | $17,640.93 |
DisclosureSEC source: 0000950170-25-010137 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,901 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:09 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 42,500 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0000950170-25-002072 · ownership.xml · derivative · entry 4 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2035-01-01 F4 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:09 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002072 · ownership.xml · nonDerivative · entry 2 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,142 F3 · shares: Grant of RSUs. The RSUs vest in full on 1/26/27. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:09 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002072 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,892 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/26, 1/26/27, 1/26/28 and 1/26/29. F2 · balance_after: Includes 2,499 shares acquired on May 17, 2024 and 50 shares acquired on November 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 963 | $17.80 | $17,141.88 |
DisclosureSEC source: 0000950170-24-009496 · ownership.xml · nonDerivative · entry 3 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,093 F3 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 761 | $17.80 | $13,546.18 |
DisclosureSEC source: 0000950170-24-009496 · ownership.xml · nonDerivative · entry 2 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,056 F2 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 594 | $17.80 | $10,573.50 |
DisclosureSEC source: 0000950170-24-009496 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,817 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 42,500 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0000950170-24-001850 · ownership.xml · derivative · entry 3 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2034-01-01 F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:08 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-001850 · ownership.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,411 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28. F2 · balance_after: Includes 1,489 shares acquired on May 17, 2023 and 206 shares acquired on November 17, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:15 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 63,750 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0001209191-23-011289 · doc4.xml · derivative · entry 3 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2033-02-15 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:15 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011289 · doc4.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,466 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/24, 1/26/25, 1/26/26 and 1/26/27. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:14 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 866 | $13.89 | $12,028.91 |
DisclosureSEC source: 0001209191-23-005746 · doc4.xml · nonDerivative · entry 2 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,841 F3 · acquired: Sell-to cover for taxes associated with the vesting of RSUs received by the Reporting Person dated 2/7/22. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:14 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 682 | $13.89 | $9,472.84 |
DisclosureSEC source: 0001209191-23-005746 · doc4.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,707 F1 · acquired: Sell-to cover for taxes associated with the vesting of RSUs received by the Reporting Person dated 1/26/22. F2 · balance_after: Includes 1,806 shares acquired on May 17, 2022 and 1,583 shares acquired on November 17, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 22:50 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 39,281 | $0.00 Strike: $13.14 | $0.00 |
DisclosureSEC source: 0001209191-22-008156 · doc4.xml · derivative · entry 3 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,281 Underlying: Common Stock · 39,281 shares Expires 2032-02-06 F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 22:50 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 8,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008156 · doc4.xml · nonDerivative · entry 1 DOYLE THOMAS JAMES · CIK 0001910331 · SVP, Finance & Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.